Publication | Closed Access
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes
78
Citations
11
References
2014
Year
Hematological MalignancyTumor BiologyBcr-jak2 Fusion GenesMedicineHematologyPathologyComplete RemissionLimited DurationOncologyCell BiologyCancer ResearchMyeloid Neoplasia
| Year | Citations | |
|---|---|---|
Page 1
Page 1